AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of its treatment for acute hepatitis C. The final ...

Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...

Nontargeted screening in emergency departments (EDs) identified significantly more new hepatitis C virus (HCV) infections than targeted screening, according to a randomized trial. Treatment completion ...

Treating hepatitis C virus (HCV) earlier in kids was associated with better lifetime clinical outcomes and lower healthcare costs compared with deferring treatment, a modeling study showed. Projected ...

As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...

The US government has set a goal of achieving viral clearance in 80% of patients by 2030. The study’s authors say the report shows there is still much work to be done to increase access to DAAs and ...

When managing patients with hepatitis C virus (HCV), initiating treatment of the infection promptly is more important than determining the severity of their liver disease with the customary staging ...